Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru

Background Rapid IgM/IgG antibody tests were largely used in lieu of RT-PCR tests as part of COVID-19 public health response activities in Lima, Peru. To assess their utility, we explored the relationship between the time since onset of several COVID-19-related symptoms and the sensitivity of a rapi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC infectious diseases Jg. 23; H. 1; S. 62 - 9
Hauptverfasser: Law, Stephanie, Tovar, Marco A., Franke, Molly F., Calderon, Roger, Palomino, Santiago, Valderrama, Gissella, Llanos, Fernando, Velásquez, Gustavo E., Mitnick, Carole D., Lecca, Leonid
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 02.02.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
Analysis
Antibodies
Antibodies, Viral - analysis
Antigens
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 Testing
Diagnostic tests
Fever
Humans
Hypothesis testing
IgG antibody
Immunoglobulin G
Immunoglobulin G - analysis
Immunoglobulin M
Immunoglobulin M - analysis
Immunoglobulins
Infectious Diseases
Internal Medicine
Laboratories
Medical Microbiology
Medicine
Medicine & Public Health
Pandemics
Parasitology
Peru
Peru - epidemiology
Polymerase chain reaction
Public health
Regression analysis
Reverse Transcriptase Polymerase Chain Reaction
RNA polymerase
SARS-CoV-2 - genetics
SARS-CoV-2 antibody testing
Sensitivity analysis
Sensitivity and Specificity
Serology
Severe acute respiratory syndrome coronavirus 2
Testing
Tropical Medicine
Vaccination
Viral antibodies
Peru
Lima Peru
COVID-19
SARS-CoV-2 antibody testing
Peru
ISSN:1471-2334, 1471-2334
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Rapid IgM/IgG antibody tests were largely used in lieu of RT-PCR tests as part of COVID-19 public health response activities in Lima, Peru. To assess their utility, we explored the relationship between the time since onset of several COVID-19-related symptoms and the sensitivity of a rapid combined IgM/IgG antibody test. Methods We collected data from a community sample of individuals (n = 492) who received concurrent RT-PCR and rapid IgM/IgG antibody testing between May 2020 and March 2021. We estimated the sensitivity of the antibody test, against the RT-PCR test, by weeks since symptom onset via segmented regression analysis. Results The overall sensitivity of the rapid IgM/IgG antibody test was 46.7% (95% CI, 42.4–51.2%). Among 372 (75.6%) participants who reported COVID-19-related symptoms, sensitivity increased from 30.4% (95% CI, 24.7–36.6%) in week 1 after symptom onset to 83.3% (95% CI, 41.6–98.4%) in week 4. The test sensitivity increased by 31.9% (95% CI, 24.8–39.0%) per week until week 2 to 3, then decreased by − 6.0% (95% CI, − 25.7–13.7%) per week thereafter. Conclusion Rapid antibody tests are a poor substitute for RT-PCR testing, regardless of presenting symptoms. This highlights the need for future pandemic planning to include timely and equitable access to gold-standard diagnostics, treatment, and vaccination.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-023-08003-7